These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6145042)

  • 1. First use of nafazatrom, a new antithrombotic drug, in pregnancy.
    Elder MG; Myatt L
    Lancet; 1984 Jun; 1(8390):1350. PubMed ID: 6145042
    [No Abstract]   [Full Text] [Related]  

  • 2. Protective actions of nafazatrom in traumatic shock.
    Lefer AM; Messenger M
    Arzneimittelforschung; 1982; 32(9):1089-91. PubMed ID: 6890831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nafazatrom in treatment of thrombotic thrombocytopenic purpura.
    Durrant ST; Joosten P; Gordon-Smith EC
    Lancet; 1985 Oct; 2(8459):842. PubMed ID: 2864567
    [No Abstract]   [Full Text] [Related]  

  • 4. Beneficial effects of nafazatrom on ischemic reperfused myocardium.
    Shea MJ; Murtagh JJ; Jolly SR; Abrams GD; Pitt B; Lucchesi BR
    Eur J Pharmacol; 1984 Jun; 102(1):63-70. PubMed ID: 6479219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of nafazatrom on cardiovascular, sympathetic, and endocrine responses to hemorrhagic shock in conscious rats.
    Feuerstein G; Bayorh MA; Stull R; Goldstein DS; Zerbe RL; Ramwell PW; Faden AI
    Circ Shock; 1985; 17(3):223-32. PubMed ID: 3841032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The beneficial effects of nafazatrom (BAYg6575) on experimental coronary thrombosis.
    Shea MJ; Driscoll EM; Romson JL; Pitt B; Lucchesi BR
    Am Heart J; 1984 Apr; 107(4):629-37. PubMed ID: 6702555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigations on the role of arachidonic acid metabolism pathways in the antithrombotic activity of nafazatrom and molsidomine.
    Massad L; Plotkine M; Boulu RG
    Thromb Res; 1988 Jun; 50(5):617-25. PubMed ID: 3137682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of nafazatrom and indomethacin on experimental myocardial ischemia in the anesthetized dog.
    Fiedler VB; Mardin M
    J Cardiovasc Pharmacol; 1985; 7(5):983-9. PubMed ID: 2413312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications.
    Zotz RB; Gerhardt A; Scharf RE
    J Thromb Haemost; 2004 Jul; 2(7):1182-92. PubMed ID: 15219203
    [No Abstract]   [Full Text] [Related]  

  • 10. The relationship between dose, pharmacokinetics, plasma-concentrations and antithrombotic effects of nafazatrom.
    Philipp E; Ritter W; Patzschke K
    Thromb Res Suppl; 1983; 4():129-33. PubMed ID: 6579706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reaction of the antithrombotic and antimetastatic agent, nafazatrom, with oxidizing radicals.
    Sevilla MD; Neta P; Marnett LJ
    Biochem Biophys Res Commun; 1983 Sep; 115(3):800-6. PubMed ID: 6312995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of acute myocardial ischemia in rabbit hearts by nafazatrom.
    Fiedler VB
    J Cardiovasc Pharmacol; 1984; 6(2):318-24. PubMed ID: 6200722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nafazatrom (Bay g-6575), an antithrombotic and antimetastatic agent, inhibits 15-hydroxyprostaglandin dehydrogenase.
    Wong PY; Chao PH; McGiff JC
    J Pharmacol Exp Ther; 1982 Dec; 223(3):757-60. PubMed ID: 6754908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laser-induced thrombi in rat mesenteric vessels and antithrombotic drugs.
    Weichert W; Pauliks V; Breddin HK
    Haemostasis; 1983; 13(1):61-71. PubMed ID: 6132858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom.
    Marnett LJ; Siedlik PH; Ochs RC; Pagels WR; Das M; Honn KV; Warnock RH; Tainer BE; Eling TE
    Mol Pharmacol; 1984 Sep; 26(2):328-35. PubMed ID: 6434940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy tests ahead for antimetastatic agent.
    Merz B
    JAMA; 1983 May; 249(19):2605. PubMed ID: 6842760
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of thrombosis during pregnancy.
    Inbal A
    Isr Med Assoc J; 2002 Oct; 4(10):813-4. PubMed ID: 12389348
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of prostaglandin modulators on prostate tumor growth and metastasis.
    Drago JR; Al-Mondhiry HA
    Anticancer Res; 1984; 4(6):391-4. PubMed ID: 6393859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies.
    Rosove MH; Tabsh K; Wasserstrum N; Howard P; Hahn BH; Kalunian KC
    Obstet Gynecol; 1990 Apr; 75(4):630-4. PubMed ID: 2107479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of thrombosis during pregnancy.
    Vilela VS; de Jesús NR; Levy RA
    Isr Med Assoc J; 2002 Oct; 4(10):794-7. PubMed ID: 12389343
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.